A Study to Assess Ulimorelin in Healthy Subjects

Summary

A Phase I dose escalation study involving healthy subjects.

Timeline

Start

2015-01

Primary completion

2015-11

Completion

2015-11

Outcome

Mixed primary results

paper Ulimorelin 150-600 µg kg-1 every 8 hours resulted in statistically significant improvements (∆t50 = 23% to 46% (P < .05)) in gastric emptying from baseline PMID 32017341 ↗

paper However, no effects on GC24 were observed. PMID 32017341 ↗

Publications

• James J, Mair S, Doll W, Sandefer E, Wurtman D, Maurer A, Deane AM, Harris MS. The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans. Neurogastroenterol Motil. 2020 Mar;32(3):e13784. doi: 10.1111/nmo.13784. Epub 2020 Feb 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ulimorelin	Small molecule	80 ug/kg	—
Subject	Ulimorelin	Small molecule	600 ug/kg	—
Subject	Ulimorelin	Small molecule	1200 ug/kg	—

Indications

No indication recorded.